Biotech Firm Developing Anti-Aging Therapy to Present at Prestigious Klotho Conference

Avaí Bio's joint venture Klothonova to showcase data on genetically modified, encapsulated cells producing longevity protein α-Klotho

Apr. 10, 2026 at 1:55pm

Got story updates? Submit your updates here. ›

A highly structured abstract painting in muted earth tones, featuring sweeping geometric shapes, intersecting waveforms, and precise botanical spirals, conceptually representing the complex biological processes involved in Avaí Bio's α-Klotho anti-aging therapy.Avaí Bio's innovative approach to restoring declining levels of the longevity protein α-Klotho could unlock new frontiers in the rapidly growing field of anti-aging biotechnology.Las Vegas Today

Avaí Bio, Inc. (OTCQB: AVAI) and its joint venture partner Austrianova announced they will present the latest data from their α-Klotho anti-aging therapy at the Second Annual Klotho Conference in September. The presentation will focus on the production of the longevity protein α-Klotho from genetically modified and encapsulated cells, an approach designed to sustainably restore circulating α-Klotho levels and support potential therapeutic applications in aging and related conditions.

Why it matters

The global longevity biotech market is projected to reach $29.7 billion by 2034, as cellular therapies, gene editing, and metabolic drugs advance from animal studies into human trials. Avaí Bio's α-Klotho program represents a differentiated approach that leverages Austrianova's clinically-validated cell encapsulation expertise to potentially restore declining levels of this key longevity protein.

The details

Klothonova, AVAI's joint venture with Austrianova, is applying the Cell-in-a-Box® encapsulation platform to protect genetically modified cells that overexpress α-Klotho, the longevity protein whose circulating levels decline sharply with age. Austrianova brings over 50 peer-reviewed publications and decades of GMP-grade cell encapsulation expertise to the partnership, while AVAI's second program 'Insulinova' targets diabetes, overlapping with one of the fastest-growing therapeutic segments in anti-aging medicine.

  • Avaí Bio and Austrianova announced the Klotho Conference presentation on April 7, 2026.
  • The Second Annual Klotho Conference is scheduled for September 2026.

The players

Avaí Bio, Inc.

An emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging.

Austrianova

A leading biotechnology company specializing in cell encapsulation, GMP-grade cell products, and cell line development, with over 50 peer-reviewed publications and partnerships with global pharmaceutical and biotech companies.

Klothonova

Avaí Bio's joint venture company with Austrianova, applying the Cell-in-a-Box® encapsulation platform to produce the longevity protein α-Klotho.

Makoto Kuro-o

The physician-scientist widely recognized for discovering the Klotho gene.

Carmen Abrahams

A Harvard-trained neuroscientist who invited Austrianova and Avaí Bio to present at the Klotho Conference.

Got photos? Submit your photos here. ›

What they’re saying

“We look forward to sharing the latest data from Klothonova's progress in α-Klotho production from encapsulated cells at this prestigious forum.”

— Brian Salmons, Chief Executive Officer of Austrianova

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.